Data as of Oct 20
| +0.445 / +1.11%|
The 16 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 44.94, with a high estimate of 52.88 and a low estimate of 35.46. The median estimate represents a +11.27% increase from the last price of 40.39.
The current consensus among 17 polled investment analysts is to Hold stock in Novozymes A/S. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.